Literature DB >> 7562592

5-Hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals.

P A Pierce1, G X Xie, S J Peroutka, P G Green, J D Levine.   

Abstract

5-Hydroxytryptamine (5-HT) is known to act in peripheral tissues to produce pain and inflammation, yet the mechanisms underlying 5-HT-induced inflammation have not been well studied. The present study uses a rat knee joint model of inflammation (synovial plasma extravasation) and molecular biological techniques to determine the site of action of 5-HT and the specific 5-HT receptor subtype mediating synovial 5-HT-induced plasma extravasation. 5-HT (1 microM) stimulates synovial plasma extravasation 7-fold above base-line levels. Surgical lumbar sympathectomy, but not C-fiber depletion by neonatal capsaicin, dramatically reduces 5-HT-induced synovial plasma extravasation (P < .001), indicating that sympathetic efferents mediate this effect. Polymerase chain reaction amplification of 5-HT receptor cDNA demonstrates that 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A and 5-HT3, but not the 5-HT2C, receptor subtypes are present in lumbar sympathetic ganglia. With selective ligands for these receptor subtypes, we demonstrate that 5-HT-induced synovial plasma extravasation is mediated via the 5-HT2A receptor. These findings suggest a role for 5-HT2A antagonists in various synovial inflammatory pain states.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562592

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Expression of 5-HT2A and 5-HT1B receptor mRNA in blood vessels.

Authors:  S Kato; H Kumamoto; M Hirano; H Akiyama; N Kaneko
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

2.  The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors.

Authors:  Karla P Zeitz; Nicolas Guy; Annika B Malmberg; Sahera Dirajlal; William J Martin; Linda Sun; Douglas W Bonhaus; Cheryl L Stucky; David Julius; Allan I Basbaum
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 3.  Wishing away inflammation? New links between serotonin and TNF signaling.

Authors:  Martin Pelletier; Richard M Siegel
Journal:  Mol Interv       Date:  2009-12

4.  Decreased density of serotonin 5-HT2A receptors in rheumatoid arthritis.

Authors:  A Kling; S Rantapää-Dahlqvist; H Stenlund; T Mjörndal
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

Review 5.  Psychedelics and Anti-inflammatory Activity in Animal Models.

Authors:  Thomas W Flanagan; Charles D Nichols
Journal:  Curr Top Behav Neurosci       Date:  2022

6.  Serotonin enhances urinary bladder nociceptive processing via a 5-HT3 receptor mechanism.

Authors:  Jason D Hall; Cary DeWitte; Timothy J Ness; Meredith T Robbins
Journal:  Neurosci Lett       Date:  2015-08-03       Impact factor: 3.046

7.  Receptor mediation and nociceptin inhibition of bradykinin-induced plasma extravasation in the knee joint of the rat.

Authors:  Kumi Moriyama; Jia Liu; Yeon Jang; Yun Jeong Chae; Yan Wang; James Mitchell; Stefan Grond; Xiaokang Han; Yilei Xing; Guo-xi Xie; Pamela Pierce Palmer
Journal:  Inflamm Res       Date:  2009-06-21       Impact factor: 4.575

8.  The pharmacological profile of ovalbumin-induced paw oedema in rats.

Authors:  R F G Feitosa; G B Melcíades; A M S Assreuy; M F G Rocha; R A Ribeiro; A A M Lima
Journal:  Mediators Inflamm       Date:  2002-06       Impact factor: 4.711

9.  Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis.

Authors:  Sigvard Kopp; Per Alstergren
Journal:  Mediators Inflamm       Date:  2002-08       Impact factor: 4.711

10.  A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.

Authors:  Niklas Palmqvist; Max Siller; Cecilia Klint; Anders Sjödin
Journal:  J Inflamm (Lond)       Date:  2016-06-22       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.